United States · FDA National Drug Code directory
ORPHENADRINE CITRATE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 43063-407_47d2a4d7-5572-e023-e063-6394a90a3617
- Product NDC
- 43063-407
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- ORPHENADRINE CITRATE
- Labeler
- PD-Rx Pharmaceuticals, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 19980619
- Source listing expiry
- 20271231
Source-listed ingredients
- ORPHENADRINE CITRATE — 100 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 14 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-407-14) · 43063-407-14
- 20 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-407-20) · 43063-407-20
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-407-30) · 43063-407-30
- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43063-407-60) · 43063-407-60
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →